Recro Pharma Reports Year End 2017 Financial Results

Recro Pharma (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospital and other acute care settings, today reported financial results for the year ended December 31, 2017.

As quoted in the press release:

“As we await the upcoming review decision from the U.S. Food and Drug Administration (FDA) for intravenous (IV) meloxicam, we are building our commercial infrastructure and preparing for our first potential product launch during 2018,” said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. “We have designed an efficient commercialization team and strategy that we believe can successfully launch IV meloxicam, pending approval, and rapidly build physician awareness, drive adoption and create meaningful value for all of our stakeholders.”

Click here to read the full press release.